CR10032A - Preparación sólida - Google Patents

Preparación sólida

Info

Publication number
CR10032A
CR10032A CR10032A CR10032A CR10032A CR 10032 A CR10032 A CR 10032A CR 10032 A CR10032 A CR 10032A CR 10032 A CR10032 A CR 10032A CR 10032 A CR10032 A CR 10032A
Authority
CR
Costa Rica
Prior art keywords
insulin sensitizer
solid preparation
active ingredient
coated
particles
Prior art date
Application number
CR10032A
Other languages
English (en)
Inventor
Kiyoshima Kenichiro
Nakamura Kenji
Kawano Tetsuya
Misaki Masafumi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37951491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10032(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR10032A publication Critical patent/CR10032A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención pretende proporcionar una preparación sólida que contiene un sensibilizador de insulina y un ingrediente activo distinto de un sensibilizador de insulina, y exhibe comportamientode disolución de un sensibilizador de insulina similar al de un sensibilizador de insulina proveniente de "una preparación sólida que solo contiene un sensibilizador de insulina como ingrediente activo". La preparación sólida comprende "una parte que contiene partículas recubiertas en donde las partículas que contienen un sensibilizador de insulina están recubiertas con lactosa o un alcohol de azúcar" y "una parte que contiene un ingrediente activo distinto de un sensibilizador de insulina".
CR10032A 2005-12-22 2008-05-30 Preparación sólida CR10032A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005370375 2005-12-22

Publications (1)

Publication Number Publication Date
CR10032A true CR10032A (es) 2008-10-03

Family

ID=37951491

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10032A CR10032A (es) 2005-12-22 2008-05-30 Preparación sólida

Country Status (24)

Country Link
US (1) US8071130B2 (es)
EP (1) EP1962811B1 (es)
JP (1) JP5179363B2 (es)
KR (1) KR20080080126A (es)
CN (1) CN101384251B (es)
AR (1) AR058605A1 (es)
AU (1) AU2006328328B2 (es)
BR (1) BRPI0620020A2 (es)
CA (1) CA2633149C (es)
CR (1) CR10032A (es)
ES (1) ES2576258T3 (es)
GE (1) GEP20115245B (es)
HR (1) HRP20160679T1 (es)
IL (1) IL191774A0 (es)
MA (1) MA30061B1 (es)
MY (1) MY149306A (es)
NO (1) NO20083104L (es)
NZ (1) NZ569071A (es)
PE (1) PE20110019A1 (es)
RU (1) RU2426530C2 (es)
TW (1) TWI384985B (es)
UA (1) UA91729C2 (es)
WO (1) WO2007072992A2 (es)
ZA (1) ZA200805147B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY146781A (en) 2006-05-23 2012-09-28 Takeda Pharmaceutical Oral preparation comprising pioglitazone
TW201350143A (zh) 2007-02-01 2013-12-16 Takeda Pharmaceutical 固體型製劑
EP2184056B1 (en) * 2007-08-27 2019-04-24 Asahi Kasei Kabushiki Kaisha Process for production of tablets containing both crystalline cellulose and granules
SG173044A1 (en) * 2009-01-23 2011-08-29 Hanmi Holdings Co Ltd Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
MX337603B (es) * 2009-11-30 2016-03-10 Adare Pharmaceuticals Inc Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion.
CN101804056A (zh) * 2010-04-16 2010-08-18 山东新华制药股份有限公司 盐酸吡格列酮、格列美脲的复方片剂及制备方法
EP2611434A1 (en) 2010-09-01 2013-07-10 Lupin Limited Pharmaceutical composition comprising metformin and pioglitazone
EP2618827B1 (en) * 2010-09-21 2021-06-02 Intekrin Therapeutics, Inc. Antidiabetic solid pharmaceutical compositions
FR2966828B1 (fr) * 2010-11-02 2012-12-28 Roquette Freres Poudre de polysaccharide et de polyol, comprimable et de haute viscosite
WO2013034174A1 (en) 2011-09-06 2013-03-14 ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. Solid preparations of pioglitazone and glimepiride
US9592296B2 (en) * 2011-09-08 2017-03-14 Hexal Ag Pharmaceutical composition for oral administration with a statin
AP2014007645A0 (en) 2011-10-21 2014-05-31 Takeda Pharmaceutical Sustained-release preparation
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
CN102641280A (zh) * 2012-04-23 2012-08-22 重庆康刻尔制药有限公司 一种盐酸吡格列酮格列美脲组合药物、片剂及其应用
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
US20160331689A1 (en) * 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
KR101782119B1 (ko) * 2016-02-01 2017-10-23 주식회사 한독 테넬리글립틴 및 설포닐우레아계 약물을 포함하는 정제
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
GB202001237D0 (en) * 2020-01-29 2020-03-11 Sisteks D O O Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product
CN111410687B (zh) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 一种长效glp-1化合物
CN115721612B (zh) * 2021-08-26 2024-07-26 上海宣泰医药科技股份有限公司 一种恩扎卢胺固体制剂颗粒及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3152978B2 (ja) 1991-12-17 2001-04-03 塩野義製薬株式会社 二層錠およびその製造方法
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
EP1671637A3 (en) 1997-06-18 2007-12-19 SmithKline Beecham P.L.C. Treatment of diabetes with thiazolidinedione and sulphonylurea
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
ES2237121T3 (es) * 1998-07-28 2005-07-16 Takeda Pharmaceutical Company Limited Preparacion solida disgregable rapidamente.
WO2000028989A1 (en) 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
RU2242244C2 (ru) 1999-01-14 2004-12-20 Амилин Фармасьютикалз, Инк. Новые композиции агонистов эксендина и способы их введения
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
JP4284017B2 (ja) * 2000-10-06 2009-06-24 武田薬品工業株式会社 固形製剤
US7510728B2 (en) * 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
RU2177318C1 (ru) 2000-12-21 2001-12-27 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция с антидиабетическим действием и способ ее получения
US20040147584A2 (en) * 2001-12-05 2004-07-29 Aventis Pharma S.A. 1,3-diarylprop-2-en-1-ones, compositions containing them and use thereof
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2003281181A1 (en) 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Process for producing coated preparation
US7332514B2 (en) 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
WO2004067001A1 (ja) 2003-01-29 2004-08-12 Takeda Pharmaceutical Company Limited 被覆製剤の製造法
US20040147564A1 (en) 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
WO2004069229A1 (en) * 2003-02-05 2004-08-19 Ipca Laboratories Limited Dual release anti-diabetic drugs and process of production thereof
WO2004091587A1 (en) * 2003-04-17 2004-10-28 Ipca Laboratories Limited Multiple release anti-diabetic drugs and process of production thereof
US20060280794A1 (en) 2003-06-06 2006-12-14 Naoru Hamaguchi Solid pharmaceutical preparation
KR20060105431A (ko) 2003-06-27 2006-10-11 닥터 레디스 리서치 파운데이션 발라글리타존 및 당뇨병치료제 화합물을 포함하는 조성물
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
JP4361461B2 (ja) * 2003-10-31 2009-11-11 武田薬品工業株式会社 固形製剤
TWI339586B (en) * 2003-10-31 2011-04-01 Takeda Chemical Industries Ltd Solid preparation comprising pioglitazone or salt thereof,glimpiride and polyoxyethylene sorbitan fatty acid ester
US8263121B2 (en) 2004-04-14 2012-09-11 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
WO2005102290A1 (en) * 2004-04-22 2005-11-03 Ranbaxy Laboratories Limited Pharmaceutical compositions of a biguanide and a sulfonylurea

Also Published As

Publication number Publication date
EP1962811A2 (en) 2008-09-03
RU2008130074A (ru) 2010-01-27
RU2426530C2 (ru) 2011-08-20
CN101384251A (zh) 2009-03-11
KR20080080126A (ko) 2008-09-02
WO2007072992A2 (en) 2007-06-28
CA2633149C (en) 2015-06-30
ES2576258T3 (es) 2016-07-06
TW200731971A (en) 2007-09-01
MA30061B1 (fr) 2008-12-01
AU2006328328A1 (en) 2007-06-28
UA91729C2 (ru) 2010-08-25
WO2007072992A3 (en) 2007-12-06
US20090028939A1 (en) 2009-01-29
PE20110019A1 (es) 2011-01-27
AU2006328328B2 (en) 2012-08-30
MY149306A (en) 2013-08-30
IL191774A0 (en) 2008-12-29
CN101384251B (zh) 2014-09-03
NO20083104L (no) 2008-09-19
HRP20160679T1 (hr) 2016-07-15
BRPI0620020A2 (pt) 2011-10-25
CA2633149A1 (en) 2007-06-28
JP5179363B2 (ja) 2013-04-10
NZ569071A (en) 2011-01-28
EP1962811B1 (en) 2016-04-27
TWI384985B (zh) 2013-02-11
GEP20115245B (en) 2011-06-27
ZA200805147B (en) 2010-05-26
AR058605A1 (es) 2008-02-13
US8071130B2 (en) 2011-12-06
JP2009520681A (ja) 2009-05-28

Similar Documents

Publication Publication Date Title
AR058605A1 (es) Preparacion solida
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
GEP20105083B (en) A solid pharmaceutical dosage formulation
WO2007067044A3 (en) Modified active-ingredient-containing pellets/capsules
NO20071667L (no) Farmasoytisk preparat omfattende levetiracetam og fremgangsmate for fremstilling av preparatet
WO2007127158A3 (en) Modification of percutaneous absorption of topically active materials
WO2009117130A3 (en) Extended release forumulation containing a wax
WO2009072007A3 (en) Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
TW200745103A (en) Substituted 7-azaindazoles, compositions containing them, production process and use
WO2008128775A3 (en) Stabilised pharmaceutical composition containing pregabaline
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
UY31452A1 (es) Recubrimiento mejorado de tableta
WO2009038095A1 (ja) セサミン類とビタミンｂ１類とを配合した組成物
BRPI0620229A8 (pt) formulação
WO2007005941A3 (en) Liver targeted conjugates
WO2009139504A3 (en) A solid pharmaceutical formulation
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
WO2011058336A3 (en) Tablet comprising gum arabic
WO2008041116A3 (en) Formulations of active principles incorporated in slns suitable for transdermal administration
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
WO2008127283A3 (en) Engineered metabolic pathways

Legal Events

Date Code Title Description
FC Refusal
FC Refusal